ASCO Issues New Guidelines for Systemic Thyroid Cancer Therapy Amid Rapid Molecular Advances
核心洞察
ASCO convened a multidisciplinary panel to create new evidence-based recommendations for systemic treatment across all thyroid cancer subtypes, including anaplastic, medullary, and well-differentiated disease.
The guidelines emphasize upfront molecular testing for advanced or aggressive thyroid cancer to identify actionable targets such as RET (搜索) alterations and BRAF (搜索)/MEK (搜索) mutations.
For anaplastic thyroid cancer (搜索), the combination of dabrafenib/trametinib with pembrolizumab immunotherapy has shown remarkable results, transforming outcomes in a historically dismal disease.
The American Society of Clinical Oncology (ASCO) has released new clinical practice guidelines for systemic therapy in thyroid cancer, reflecting the rapid expansion of molecularly targeted treatment options that are reshaping the therapeutic landscape. The multidisciplinary panel's recommendations span well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer (搜索) subtypes.
"We're now able to target molecular aberrations and treat thyroid cancer in ways that we never could in the past," said ASCO panel expert Joseph Scharpf, MD, Director of Head & Neck Endocrine Surgery at Cleveland Clinic. "Traditionally, treatment involved surgery or radioactive iodine but that has shifted. Surgeons, radiation oncologists, medical oncologists and endocrinologists need evidence-based recommendations about the various agents and targets now available and how best to coordinate care."
Molecular Testing Takes Center Stage
The guidelines highlight the critical importance of molecular testing for patients with advanced or aggressive thyroid cancer, ideally performed in the upfront setting. Such testing can identify potential targeted treatments for many patients, including those harboring RET (搜索) alterations. The panel noted that the tremendous growth in understanding of the molecular basis of thyroid cancer has brought new opportunities for targeted treatment, with patients now having options including targeted therapy, multikinase inhibitors, or immunotherapy alongside traditional surgical or radioiodine approaches.
Immunotherapy: Not One-Size-Fits-All
A key distinction emphasized by the panel is that immunotherapy is not uniformly appropriate across all thyroid cancer types. Specifically, pembrolizumab immunotherapy is not intended for patients with medullary thyroid cancer (搜索). This nuanced guidance aims to prevent inappropriate application of immunotherapeutic strategies where they lack demonstrated benefit.
Anaplastic Thyroid Cancer (搜索): A Changing Prognosis
Perhaps the most striking transformation has occurred in anaplastic thyroid cancer (搜索), a historically devastating disease. Patients with this fast-moving cancer often present in the emergency room with trouble breathing or swallowing. "Traditionally, patients with anaplastic thyroid cancer had dismal outcomes, but now agents like dabrafenib and trametinib can target BRAF (搜索) and MEK (搜索) mutations in roughly half of these patients," Dr. Scharpf explained. "Together with pembro immunotherapy, many patients are seeing remarkable results. We often treat aggressive disease in my practice, and this approach has been a game changer."
The guidelines also raised awareness about agents capable of controlling distant metastases, even for some of the most challenging cases such as anaplastic thyroid cancer (搜索).
Multidisciplinary Coordination and Personalized Care
The ASCO panel stressed that treatment selection and sequencing decisions are best made with a multidisciplinary tumor board. While radioiodine still plays an integral role in treating thyroid cancer, there is a movement toward personalizing its use, with some patients who have more favorable disease profiles potentially not requiring this therapy.
Additionally, while surgery remains the standard of care, targeted agents can be used in some instances to lessen the degree of surgical intervention needed—a particularly beneficial approach when surgery involves risk to nerves or the windpipe.
Cleveland Clinic Cancer Institute, which participated in drafting the ASCO guidelines, continues to contribute to thyroid cancer research, including a recently published study of anaplastic thyroid cancer (搜索) treatment and a new trial investigating the oral tyrosine kinase inhibitor zanzatinib (搜索) for invasive thyroid cancer.